Alimta

... dBusinessNews :: Daily Business News Delivered to Your Desktop Home Login/Register Post Story Classified Ads Subscribe Advertise About DBN Contact Us Wednesday, October 26, 2005 Find news from your area Select Region Albany Anchorage Atlanta Augusta Austin Baltimore Billings Birmingham Bismarck Boise Boston Charleston Charlotte Cheyenne Chicago Cincinnati Cleveland Columbia Columbus Concord Dallas Dayton Denver Des Moines Detroit Hampton Roads Hartford Honolulu Houston Indianapolis Jackson Jacksonville Kansas City Las Vegas Little Rock Los Angeles Louisville Memphis Milwaukee Minneapolis Montpelier Nashville New Orleans New York Newark Oklahoma City Omaha Orange County Orlando Philadelphia Phoenix Pittsburgh Portland Potomac Providence Richmond Sacramento Salt Lake City San Antonio San Francisco San Jose Seattle Sioux Falls South Florida St.Louis Tampa Triad Triangle Wichita Wilmington Latest News Hartford: Applied Biosystems Assays and Microarray Products Are Now Referenced from Genomic Data Newly Available Through the National Institutes of Health Hartford - Gene Annotation and SNP Data Will Have Broad-Reaching ...Hartford: IMS Health Forecasts 6 to 7 Percent Growth for Global Pharmaceutical Market in 2006; U.S.

Forecast to Grow at 8 to 9 Percent Pace, Up from 6 to 7 Percent in 2005; China Market Remains Robust, Growing 17 to 18 Percent Hartford - IMS Health (NYSE: RX), the world's leading provider ...Hartford: Zusammenfa...

... home Unternehmen Ad hoc-News TecDax IT & Media Marktberichte Analysen FondsNews Branchen Konjunktur & Politik Kommentare Investor Relations Business Wire DGAP Corporate News Suche Suche in den News von heute Service Newsletter-Service Geschäftsberichte Newsarchiv Seminare Handhelds Börsenline Sitemap vwd group gatrixx NetSolutions GmbH gevasys mbH market maker Software AG business sector AG b.i.s börsen-informations-systeme AG Quotrix AG Weitere Beteiligungen DGAP *vwd/BUSINESS WIRE: IMS Health erwartet für 2006 ein Wachstum von 6% bis 7% für globale Pharmaindustrie DIE ÜBERSETZUNG INS DEUTSCHE ERFOLGT OHNE GEWÄHR.

VERBINDLICH IST AUSSCHLIESSLICH DIE ORIGINALMELDUNG DES EMITTENTEN.

TRANSLATION INTO GERMAN LANGUAGE IS PROVIDED WITHOUT GUARANTEE.

ONLY THE ORIGINAL MESSAGE OF THE ISSUER IS AUTHORITATIVE.

FAIRFIELD, Connecticut -(BUSINESS WIRE)-25.

Oktober 2005- IMS Health, der weltweit führende Anbieter von Informationslösungen für die Pharma- und Gesundheitsindustrie, hat heute mitgeteilt, dass das Unternehmen für 2005 für den globalen Pharmamarkt ein unverändertes Wachstum von 7% bis 8% erwartet.

Für 2006 wird ein Wachstum von 6% bis 7% mit einem Gesamtmarktvolumen von bis zu 640 Mrd bis 650 Mrd USD prognostiziert.

--------- *vwd/BUSINESS WIRE: IMS Health Forecasts 6 to...

... Netherlands Corporate News - IMS Health voorspelt 6 tot 7 procent groei voor wereldwijde farmaceu..

Zoek in het archief terug Datum nieuwsfeit: 26-10-2005 IMS Health voorspelt 6 tot 7 procent groei voor wereldwijde farmaceutische markt in 2006; Chinese markt blijft sterk, groeit 17 tot 18 procent ( BW)(CT-IMS-HEALTH)(RX) IMS Health Forecasts 6 to 7 Percent Growth for Global Pharmaceutical Market in 2006; U.S.

Forecast to Grow at 8 to 9 Percent Pace, Up from 6 to 7 Percent in 2005; China Market Remains Robust, Growing 17 to 18 Percent Business Editors/Health Editors/Science Editors FAIRFIELD, Conn.-(BUSINESS WIRE)-Oct.

25, 2005-IMS Health (NYSE: RX), the world's leading provider of information solutions to the pharmaceutical and healthcare industries, today announced that it expects global pharmaceutical market growth to remain flat in 2005 at 7 - 8 percent, and is forecasting 6 - 7 percent growth in 2006, with total market size reaching U.S.

$640 - 650 billion.

"Several key market events are expected to shape the pharmaceutical industry in 2006," said Murray Aitken, senior vice president, Corporate Strategy, IMS Health.

"These include the introduction of the Medicare drug benefit in the U.S., expected patent loss and generic introduction for six blockbuster products, and continued efforts by local governments to reduce drug spending and manage patient access to branded pharmaceuticals.

While some pharmaceutical companies are taking the necessary steps to address the...